Italian Registry of Arthritis on Biologic Therapy

Gruppo Italiano Studio Early Arthritis10,000 enrolled

Overview

The biologic drugs targeting TNFa, IL-6, IL-1, T cells, B cells have represented a fundamental discovery to treat rheumatic patients whose disease appears to be refractory to conventional therapy. These biologic drugs have been registered for human therapy from a few years, thereby the investigators miss long-term data for safety and efficacy. Aim of this study is to register all the clinical data of patients with rheumatoid arthritis and spondyloarthritis beginning a treatment with biologic drugs in order to assess the long-term safety and efficacy in the real life.

Study Type

OBSERVATIONAL

Enrollment

10,000

Conditions

Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 14 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis * Patients with active disease refractory to traditional disease modifying drugs (methotrexate, leflunomide, sulphasalazine, cyclosporine, hydrossiclorochine) * Patients eligible to begin conventional biologic therapy Exclusion Criteria: * Any criteria excluding treatment with biologic drugs according to international guidelines

Locations (1)

GISEA

Bari, Italy

RECRUITING

Central Contacts

Giovanni Lapadula, MD

CONTACT

+390805478867 g.lapadula@reumbari.uniba.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.